Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ryosuke Naka, Kohei Tada, Hitomi Kaneko, Osamu Nagata, Masaharu Tashima, Chisato Mizutani & Kazunori Imada. (2022) Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (rituximab, gemcitabine, cisplatin, and dexamethasone). Leukemia & Lymphoma 63:6, pages 1508-1511.
Read now
Read now
Rajshekhar Chakraborty, Shiva Kumar Reddy Mukkamalla, Garfield Gutzmore & Hon Cheung Chan. (2015) A case of Hodgkin’s lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVD. Journal of Blood Medicine 6, pages 93-97.
Read now
Read now
Anna Czyz, Joanna Romejko-Jarosinska, Wanda Knopinska-Posluszny, Adam Nowicki, Anna Lojko-Dankowska, Lidia Gil, Dominik Dytfeld, Jan Walewski, Andrzej Hellmann & Mieczyslaw Komarnicki. (2013) Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant. Leukemia & Lymphoma 54:5, pages 973-978.
Read now
Read now
Barbara Pro & Guilherme Fleury Perini. (2012) Brentuximab vedotin in Hodgkin's lymphoma. Expert Opinion on Biological Therapy 12:10, pages 1415-1421.
Read now
Read now
Articles from other publishers (41)
Yoshikazu Ikoma, Nobuhiko Nakamura, Junichi Kitagawa, Takao Miwa, Eri Takada, Takuro Matsumoto, Yuhei Shibata, Hiroshi Nakamura, Nobuhiro Kanemura, Senji Kasahara, Takeshi Hara, Michio Sawada, Hisashi Tsurumi & Masahito Shimizu. (2023) A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non‐Hodgkin lymphoma. Hematological Oncology.
Crossref
Crossref
Taylor R. Brooks & Paolo F. Caimi. (2023) A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Reviews, pages 101140.
Crossref
Crossref
Yu Yagi, Yusuke Kanemasa, Yuki Sasaki, Mina Sei, Takuma Matsuo, Kento Ishimine, Yudai Hayashi, Mano Mino, An Ohigashi, Yuka Morita, Taichi Tamura, Shohei Nakamura, Toshihiro Okuya, Takuya Shimizuguchi, Naoki Shingai, Takashi Toya, Hiroaki Shimizu, Yuho Najima, Takeshi Kobayashi, Kyoko Haraguchi, Noriko Doki, Yoshiki Okuyama & Tatsu Shimoyama. (2023) Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study. Cancer Medicine.
Crossref
Crossref
May Chiu, Samuel Hague, Anna Elinder-Camburn, Eileen Merriman & Henry Chan. (2022) Retrospective Analysis of the Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant. Clinical Lymphoma Myeloma and Leukemia 22:11, pages 835-840.
Crossref
Crossref
Surya K. De. 2022. Fundamentals of Cancer Detection, Treatment, and Prevention. Fundamentals of Cancer Detection, Treatment, and Prevention
67
131
.
Takahide Taniguchi, Shoko Nakayama, Hirokazu Tanaka, Shinya Rai, Chikara Hirase, Yasuyoshi Morita, Yoichi Tatsumi, Takashi Ashida, Mitsuhiro Matsuda, Shigeo Hashimoto & Itaru Matsumura. (2022)
Novel prognostic predictor of haemoglobin–platelet index in diffuse large B‐cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with
IL
‐6 production in lymphoma cells
. British Journal of Haematology 198:2, pages 360-372.
Crossref
Crossref
Takuya Matsunaga, Tomoko Deto, Tomoe Yamada, Takashi Yamamoto, Kimika Yamakawa, Yuta Kamiyama, Masako Morimoto, Hitoshi Seki, Fumihiko Haraguchi, Ikuko Hisatomi, Katsuya Nakanishi & Masahiro Takahashi. (2022)
Limitations of the
L3
skeletal muscle index and the Asian Working Group for Sarcopenia 2019 consensus diagnostic criteria for sarcopenia evaluation in a case of diffuse large B‐cell lymphoma
. Clinical Case Reports 10:6.
Crossref
Crossref
Wenhao Zhong, Xinyu Zhang, Xiao Duan, Hengyu Liu, Yifen Fang, Moucheng Luo, Zhengwen Fang, Congxiu Miao, Dongjun Lin & Jun Wu. (2022) Redox-responsive self-assembled polymeric nanoprodrug for delivery of gemcitabine in B-cell lymphoma therapy. Acta Biomaterialia 144, pages 67-80.
Crossref
Crossref
Richard T. HoppeRanjana H. AdvaniWeiyun Z. AiRichard F. AmbinderPhilippe ArmandCeleste M. BelloCecil M. BenitezWeina ChenBouthaina DabajaMegan E. DalyLeo I. GordonNeil HansenAlex F. HerreraEphraim P. HochbergPatrick B. JohnstonMark S. KaminskiChristopher R. KelseyVaishalee P. KenkreNadia KhanRyan C. LynchKami MaddocksJonathan McConathyMonika MetzgerDavid MorganCarolyn MulroneySheeja T. PullarkatRachel RabinovitchKaren C. RosenspireStuart SeropianRanda TaoPallawi TorkaJane N. WinterJoachim YahalomJoanna C. Yang, Jennifer L. BurnsMallory CampbellHema Sundar. (2022) NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. Journal of the National Comprehensive Cancer Network 20:4, pages 322-334.
Crossref
Crossref
Toshiya Hino, Akira Honda, Arika Shimura, Yosuke Masamoto & Mineo Kurokawa. (2021) R-GCD regimen in elderly patients with relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma: a retrospective single-center analysis. International Journal of Hematology 115:2, pages 296-297.
Crossref
Crossref
Tuan Tung Nguyen, Van Hung Nguyen & Minh Phuong Vu. (2022) Gemcitabine, Dexamethasone, Cisplatin with Rituximab in Treatment Transplant- Ineligible Relapsed Non-Hodgkin B-cell Lymphoma Patients. Clinical Cancer Investigation Journal 11:3, pages 15-20.
Crossref
Crossref
Ryszard Swoboda, Sebastian Giebel, Wanda Knopińska-Posłuszny, Ewa Chmielowska, Joanna Drozd-Sokołowska, Ewa Paszkiewicz-Kozik, Waldemar Kulikowski, Michał Taszner, Włodzimierz Mendrek, Jacek Najda, Tomasz Czerw, Magdalena Olszewska-Szopa, Anna Czyż, Agnieszka Giza, Wojciech Spychałowicz, Edyta Subocz, Paweł Szwedyk, Aleksandra Krzywon, Agata Wilk & Jan Maciej Zaucha. (2021) High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma. Annals of Hematology 100:7, pages 1755-1767.
Crossref
Crossref
Shunsuke Kunou, Kazuyuki Shimada, Mika Takai, Akihiko Sakamoto, Tomohiro Aoki, Tomoya Hikita, Yusuke Kagaya, Eisuke Iwamoto, Masashi Sanada, Satoko Shimada, Fumihiko Hayakawa, Chitose Oneyama & Hitoshi Kiyoi. (2021) Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma. Oncogene 40:23, pages 3989-4003.
Crossref
Crossref
Akio Onishi, Yoshihiro Inamoto, Kinuko Tajima, Junko Yamaguchi, Ichiro Kawashima, Akihisa Kawajiri, Tomonari Takemura, Ayumu Ito, Takashi Tanaka, Keiji Okinaka, Shigeo Fuji, Saiko Kurosawa, Sung-Won Kim & Takahiro Fukuda. (2020) Detrimental effects of pretransplant cisplatin-based chemotherapy on renal function after allogeneic hematopoietic cell transplantation for lymphoma. Bone Marrow Transplantation 55:11, pages 2196-2198.
Crossref
Crossref
Timothy J Voorhees & Anne W Beaven. (2020) Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma. Cancers 12:10, pages 2887.
Crossref
Crossref
Richard T. HoppeRanjana H. AdvaniWeiyun Z. AiRichard F. AmbinderPhilippe ArmandCeleste M. BelloCecil M. BenitezPhilip J. BiermanKirsten M. BoughanBouthaina DabajaLeo I. GordonFrancisco J. Hernandez-IlizaliturriAlex F. HerreraEphraim P. HochbergJiayi HuangPatrick B. JohnstonMark S. KaminskiVaishalee P. KenkreNadia KhanRyan C. LynchKami MaddocksJonathan McConathyMatthew McKinneyMonika MetzgerDavid MorganCarolyn MulroneyRachel RabinovitchKaren C. RosenspireStuart SeropianRanda TaoJane N. WinterJoachim Yahalom, Jennifer L. BurnsNdiya Ogba. (2020) Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 18:6, pages 755-781.
Crossref
Crossref
Adam Buczkowski, Michał Gorzkiewicz, Artur Stepniak, Małgorzata Malinowska-Michalak, Paweł Tokarz, Paweł Urbaniak, Maksim Ionov, Barbara Klajnert-Maculewicz & Bartlomiej Palecz. (2020) Physicochemical and in vitro cytotoxicity studies of inclusion complex between gemcitabine and cucurbit[7]uril host. Bioorganic Chemistry 99, pages 103843.
Crossref
Crossref
Young-Woong Won, Hyewon Lee, Hyeon-Seok Eom, Jin Seok Kim, Cheolwon Suh, Dok Hyun Yoon, Jung Yong Hong, Hye Jin Kang, Jae Hoon Lee, Won Seog Kim, Seok Jin Kim, Won-Sik Lee, Myung Hee Chang, Young Rok Do, Jun Ho Yi, Inho Kim, Jong-Ho Won, Kyoungha Kim, Sung Yong Oh & Jae-Cheol Jo. (2020) A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin’s lymphoma. Annals of Hematology 99:2, pages 255-264.
Crossref
Crossref
Akiko Fukunaga, Yoshio Okamoto, Sho Shibata, Shojiro Inano, Yoko Takiuchi, Kazuyo Yamamoto, Sumie Tabata & Toshiyuki Kitano. (2020) Efficacy of salvage therapy with MTX-HOPE for elderly patients with heavily pretreated non-Hodgkin’s lymphoma. Journal of Clinical and Experimental Hematopathology 60:2, pages 37-40.
Crossref
Crossref
Vicki A. Morrison. 2020. Geriatric Oncology. Geriatric Oncology
583
612
.
Marika Okuni, Kimikazu Yakushijin, Keiichiro Uehara, Hiroya Ichikawa, Hirotaka Suto, Akiko Hashimoto, Yasuhiro Tanaka, Isaku Shinzato, Rina Sakai, Yu Mizutani, Shigeki Nagao, Keiji Kurata, Seiji Kakiuchi, Yoshiharu Miyata, Yumiko Inui, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Hiroshi Matsuoka & Hironobu Minami. (2019) Successful Bridging Chemotherapy with Gemcitabine, Carboplatin, and Dexamethasone before Unrelated Stem Cell Transplantation for Hepatosplenic T-cell Lymphoma. Internal Medicine 58:5, pages 707-712.
Crossref
Crossref
Hiroki Kobayashi, Yoshiaki Abe, Daisuke Miura, Kentaro Narita, Akihiro Kitadate, Masami Takeuchi & Kosei Matsue. (2019) Limited efficacy of high-dose methotrexate in patients with neurolymphomatosis. International Journal of Hematology 109:3, pages 286-291.
Crossref
Crossref
Maya Zlotnick, Abraham Avigdor, Elena Ribakovsky, Arnon Nagler & Meirav Kedmi. (2019) Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma. Acta Haematologica 141:2, pages 84-90.
Crossref
Crossref
Jan Walewski, Andrzej Hellmann, Noppadol Siritanaratkul, Guner Hayri Ozsan, Muhit Ozcan, Suporn Chuncharunee, Ai Sim Goh, Wojciech Jurczak, Jan Koren, Ewa Paszkiewicz‐Kozik, Bingxia Wang, Shalini Singh, Dirk Huebner, Andreas Engert & Bastian von Tresckow. (2018) Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi‐agent chemotherapy. British Journal of Haematology 183:3, pages 400-410.
Crossref
Crossref
Clémentine Sarkozy & Laurie H. Sehn. (2018) Management of relapsed/refractory DLBCL. Best Practice & Research Clinical Haematology 31:3, pages 209-216.
Crossref
Crossref
Reena Nair, Abhishek Kakroo, Ajay Bapna, Ajay Gogia, Amish Vora, Anand Pathak, Anu Korula, Anupam Chakrapani, Dinesh Doval, Gaurav Prakash, Ghanashyam Biswas, Hari Menon, Maitreyee Bhattacharya, Mammen Chandy, Mayur Parihar, M. Vamshi Krishna, Neeraj Arora, Nikhil Gadhyalpatil, Pankaj Malhotra, Prasad Narayanan, Rekha Nair, Rimpa Basu, Sandip Shah, Saurabh Bhave, Shailesh Bondarde, Shilpa Bhartiya, Soniya Nityanand, Sumeet Gujral, T. V. S. Tilak & Vivek Radhakrishnan. (2018) Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group. Indian Journal of Hematology and Blood Transfusion 34:3, pages 398-421.
Crossref
Crossref
Vicki A. Morrison. 2018. Geriatric Oncology. Geriatric Oncology
1
31
.
Yogesh Jethava, Guru Subramanian Guru Murthy & Mehdi Hamadani. (2017) Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?. Hematology/Oncology and Stem Cell Therapy 10:2, pages 47-56.
Crossref
Crossref
Nathan D. Gay, Craig Y. Okada, Andy I. Chen & Emma C. Scott. (2017) Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab. Therapeutic Advances in Hematology 8:5, pages 175-180.
Crossref
Crossref
Joseph Maly & Lapo Alinari. (2016) Pembrolizumab in classical Hodgkin's lymphoma. European Journal of Haematology 97:3, pages 219-227.
Crossref
Crossref
Lapo Alinari & Kristie A. Blum. (2016) How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant. Blood 127:3, pages 287-295.
Crossref
Crossref
Rosalba Camicia, Hans C. Winkler & Paul O. Hassa. (2015) Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Molecular Cancer 14:1.
Crossref
Crossref
Jing-Shi Wang, Zhao Wang, Yi-Ni Wang, Lin Wu, Li Fu & Na Wei. (2015) Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Treatment for Relapsed or Refractory Lymphoma. Indian Journal of Hematology and Blood Transfusion 31:4, pages 426-433.
Crossref
Crossref
Maika Onishi, Solomon A. Graf, Leona Holmberg, Sanaz Behnia, Andrei R. Shustov, Karen Schiavo, Mary Philip, Edward N. Libby, Ryan D. Cassaday, John M. Pagel, Jennifer E. Roden, David G. Maloney, Damian J. Green, Brian G. Till, Oliver W. Press, Stephen D. Smith & Ajay K. Gopal. (2015) Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. Hematological Oncology 33:4, pages 187-191.
Crossref
Crossref
V.A. Morrison, P. Hamlin, P. Soubeyran, R. Stauder, P. Wadhwa, M. Aapro & S.M. Lichtman. (2015) Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. Annals of Oncology 26:6, pages 1058-1068.
Crossref
Crossref
Sarah Barton, Eliza A. Hawkes, David Cunningham, Clare Peckitt, Sue Chua, Andrew Wotherspoon, Ayoma Attygalle, Alan Horwich, Mike Potter, Mark Ethell, Claire Dearden, Mary Gleeson & Ian Chau. (2014)
Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐
GEM
‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma
. European Journal of Haematology 94:3, pages 219-226.
Crossref
Crossref
M A Kharfan-Dabaja, M Hamadani, H Sibai & B N Savani. (2014) Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!. Bone Marrow Transplantation 49:5, pages 599-606.
Crossref
Crossref
Jing Lu, Guohua Huang, Hai-Peng Li, Kai-Yan Feng, Lei Chen, Ming-Yue Zheng & Yu-Dong Cai. (2014) Prediction of Cancer Drugs by Chemical-Chemical Interactions. PLoS ONE 9:2, pages e87791.
Crossref
Crossref
Mohamad Khawandanah, Teresa Kraus & Mohamad Cherry. (2014) Refractory Classical Hodgkin Lymphoma Presenting with Atypical Cutaneous Involvement and Diagnosis of ZZ Phenotype Alpha-1 Antitrypsin Deficiency. Case Reports in Hematology 2014, pages 1-6.
Crossref
Crossref
Andres Forero‐TorresMichelle FanaleRanjana AdvaniNancy L. BartlettJoseph D. RosenblattDana A. Kennedy & Anas Younes. (2012) Brentuximab Vedotin in Transplant‐Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. The Oncologist 17:8, pages 1073-1080.
Crossref
Crossref
Erin-Siobhain R. CurrinAjay K. Gopal. (2012) Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation. The Korean Journal of Hematology 47:1, pages 8.
Crossref
Crossref